News | November 28, 2023
GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex